Melbourne, Australia, 07 January 2019: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases.
Certa Therapeutics and its management team including Chief Executive Officer, Professor Darren Kelly, will attend the 27th Annual J.P. Morgan Healthcare Conference. The Certa team will highlight their scientific advancements in the treatment of systemic sclerosis (SSc) and chronic kidney disease (CKD).
The conference will take place on 7th – 10th January 2019 in San Francisco, California. The annual event is one of the largest and most informative healthcare investment symposiums in the industry.
Certa Therapeutics is currently progressing its clinical development program for a novel therapeutic platform of precision medicines for the treatment of serious inflammatory and fibrotic diseases including SSC and CKD. Certa is using genetic analysis to identify the most suitable patients for treatment.
SSc is a rare autoimmune disease, causing inflammation and fibrosis (scarring/hardening) of the skin and other organs. There is a clear need for new innovative treatments as currently approved therapies are largely ineffective and can have significant side-effects.
There are currently no treatments available for kidney fibrosis, which presents in the majority of) patients with CKD. Given the enormous cost of dialysis and kidney transplants to the healthcare system, finding an effective treatment for these patients remains one of the global healthcare industry’s largest unmet needs.
During the J.P. Morgan Health Conference, more than 450 companies, both public and private, deliver presentations to more than 10,000 attendees. It provides a unique platform for investors and industry leaders in the biotech and pharmaceutical sector.